

Committee on Energy and Commerce
U.S. House of Representatives
Witness Disclosure Requirement – “Truth in Testimony”
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: Diana M. Zuckerman, Ph.D.		
2. Your Title: President		
3. The Entity(ies) You are Representing: National Center for Health Research		
4. Are you testifying on behalf of the Federal, or a State or local government entity? (If “Yes,” skip Item 5 and Item 6.)	Yes	No x
5. Grants, Contracts, and Payments a. Please list any <u>Federal grants or contracts</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u> . Only grants, contracts, or payments related to the subject matter of the hearing must be listed. None b. Please list any <u>contracts or payments originating with a foreign government</u> that you or the entity(ies) you represent have received <u>on or after January 1, 2023</u> . Only grants, contracts, or payments related to the subject matter of the hearing must be listed. c. None		
6. Are you a fiduciary (i.e., authorized to act on behalf of or for the benefit of) for any entity that has an interest in the subject matter of the hearing?	Yes	No x
7. Please attach your curriculum vitae to your completed disclosure form.		

Signature:

Date: 9/17/2035



CURRICULUM VITAE (Abbreviated Version)

Name: **Diana M. Zuckerman, Ph.D.**

Address: National Center for Health Research
1001 Connecticut Ave, NW, Suite 1100
Washington, DC 20036



Cell Phone:



Educational Background:

Smith College, Northampton, Massachusetts,
Psychology, B.A. 1972

Ohio State University, Columbus, Ohio, 1972-77.
Clinical Psychology, M.A. 1975; Ph.D. 1977.

Yale Medical School, New Haven, Connecticut.
Post-doctoral fellow in epidemiology/public health, 1979-80.

Clinical Internship: Worcester State Hospital, MA, 1976-77.

Areas of Expertise: Health policy, federal agency oversight, epidemiology, public health, biostatistics, research methodology, clinical trial design, comparative effectiveness research, psychology and mental health, bioethics, health education for patients and consumers

Fellowships, Grants, Honors:

Smith College Scholarship, 1968-72.

Elected to Sigma Xi (Honorary Research Society), 1972.

Mershon Center, Research Assistant on communications and public policy, Ohio State University, 1972-73.

National Institute of Mental Health Public Health Trainee: 1973-74; 1974-75; 1975-76.

State of Ohio Clinical Psychology Trainee: 1974, 1975.

Ohio State University, Psychology Department Teaching Assistant, 1976.

National Institute of Mental Health Internship, 1976-77.

National Institute of Mental Health Post-doctoral Fellowship in epidemiology, 1979-80.

American Association for the Advancement of Science, Congressional Science Fellowship, sponsored by the American Psychological Association, 1983-84.
Grant #1R03 MH38060-01, National Institute of Mental Health, research on college students' eating disorders, 1983-84.

APA Media Award as co-author of Big World, Small Screen: The Role of Television in American Society, 1992.

Listed in Who's Who of American Women

Inducted into the International Women in Medicine Hall of Fame, 2010

The Ohio State University Alumni of the Year, 2025

Principal Investigator for 27 grants from 2000-present, such as research grants from Robert Wood Johnson Foundation, Pew Charitable Trust, and Verizon Foundation; conference grants from Agency for Healthcare Research and Quality; U.S. Food and Drug Administration, U.S. Department of Health and Human Services Office for Disability; U.S. Department of Health and Human Services Office for Women's Health, grants to educate patients and journalists about research issues from the D.C. Cancer Consortium, Susan G. Komen Foundation, and the Patient Centered Outcome Research Institute (PCORI); Health Research and Policy grants from Arnold Foundation.

Boards, Committees, and Commissions

American Psychological Association: Elected fellow of the APA 1992; Board of Professional Affairs 1990-1992; Committee on Legal Issues 1990-1992; Task Force on Television and Society, 1986-88.

Society for the Psychological Study of Social Issues (Division 9): Council 1990-92; Co-Chair, Public Policy Fellow Committee, 1992-94; member of the selection committee for the James Marshall Post-doctoral Public Policy Fellow, 1992-94; Fellowship consultant 2001-2004.

Congressional Science Fellowship: Member of the post-doctoral fellowship selection committee for the American Association for the Advancement of Science, 1995 and 1996, and for the American Psychological Association, 1985 and 1986.

American Association for the Advancement of Science (AAAS): Member of the NIH Fellowship Selection Committee, 2001; Member of the AAAS Media Awards Selection Committee for TV reporting on health issues, 2001 and 2007.

National Women's Health Network: Vice Chair of the Board of Directors 1996-2000.

TMJ Association: (a patient advocacy organization) Board of Directors 1997-2004.

Commission for Women, Montgomery County, MD: Co-chair of Legislative Task Force, 1998-2001.

National Cancer Institute Scientific Advisory Committee: Advisory Committee for NCI studies on implants, 1999- present.

Girl Neighborhood Power: (a project of the U.S. Public Health Service) Member of the Steering Committee 1998-2001.

National Cancer Institute Consumer Advocates in Research and Related Activities: Founding member and designated mentor to new members, 2001-2005.

State of Maryland Work-Life Alliance: Appointed by Lt. Governor Kathleen Kennedy Townsend, 2001-2003

State of Maryland Governor's Council on Women's Health Promotion: Co-chair, 2002-2005.

Reagan-Udall Foundation: Board of Directors of Congressionally mandated foundation to strengthen the FDA, 2007-2019

Medicare Evidence Development Coverage Advisory Committee (MEDCAC), CMS, Member, 2014-2018

Alliance for a Stronger FDA: Board of Directors of nonprofit coalition of industry and nonprofit organizations, 2006-present

Medical Device Epidemiology Network (MDEpiNet): Stakeholder Council of Public- Private partnership, 2012-present

Editorial Responsibilities:

Member of the editorial board of the *Journal of Social Issues* 1997-2000; guest editor of *Journal of Social Issues* special issue on welfare reform, 2001; 1980-present regular peer reviewer for text books and journal articles in psychology, public policy, and medicine.

Health Policy Experience:

- | | |
|---------------------|---|
| 1999-present | President, National Center for Health Research
CEO of an independent, non-profit research-based public health think tank that analyzes, synthesizes, and widely disseminates evidence-based information on policy-relevant issues that affect the health and safety of adults and children. Responsibilities include obtaining initial grant and contract support and creating and building the organization; representing the organization in meetings with Congress, the White House, and federal agencies; serving as a spokesperson with the media; monitoring and reviewing research standards used by federal and State agencies. Current projects include scrutinizing programs and policies intended to improve quality of prevention strategies and health care for cancer and other serious diseases; improving safety of medical products and children's products; improving programs and policies to reduce obesity; reducing environmental exposures that harm health, bridging the gap between research findings and public information so that patients and consumers can make informed decisions. |
| 1997-98 | Director of Research and Policy Analysis, Institute for Women's Policy Research
Manage and direct Research Department and policy efforts of an independent, non-profit scientific research organization that conducts research on the full spectrum of issues affecting women and families. Co-chair for the National Council of Women's Organizations' (a coalition of 140 national organizations) Task Force on Women and Economic Security, which conducts monthly briefings for Congressional staff and policy analysts. |
| 1995-96 | Senior Policy Analyst, Office of Science and Technology Policy, The White House
Advised White House officials and staff regarding federal programs in Department of Health and Human Services and Veterans Administration Gulf War illness issues. Briefed President |

and First Lady, wrote speeches and position papers, and served as a member of White House working groups to develop policy activities and to plan and appoint a Presidential Advisory Committee, while serving in this one-year position.

1993-95

Director, Health Policy Staff, Senate Committee on Veterans' Affairs

Initiated and managed all Senate legislation and hearings on health and mental health research and services of the Department of Veterans' Affairs, which runs the largest medical system in the U.S. Advised Chairman Jay Rockefeller (D-WV) on health care reform, Gulf War illnesses, and other issues; wrote speeches, articles, and Congressional reports. Managed Committee health staff. Represented Sen. Rockefeller at meetings with White House officials, staff of Federal agencies, members of Congress and their staff, university deans and faculty, advocacy organizations, and constituents.

1993

Director of Policy, Planning and Legislation, Center for Mental Health Services

Responsible for fiscal planning and program priorities for this \$385 million mental health services agency of the U.S. Department of Health and Human Services. Established new office; hired and managed staff; and worked with Congress, other Federal agencies, experts in the field, and advocates to improve services to prevent and treat mental illness.

1985-93

Committee Professional Staff, U.S. House of Representatives

Managed numerous high-visibility public policy reviews for a subcommittee of the Government Operations Committee, including access to health care, safety of medical devices, and quality of government research programs and demonstration projects. Reviewed policies and programs of the Departments of Health and Human Services, Education, and Veterans Affairs, National Science Foundation, and the D.C. government; initiated and managed Congressional hearings; developed legislation; wrote speeches, reports, and press releases; managed the media; initiated and monitored General Accounting Office (GAO) reports requested by the Chairman; and represented the Chairman at meetings with Congress and staff, Administration officials, lobbyists, and experts in health, mental health, and social policy.

1983-84

Congressional Science Fellow, U.S. House of Representatives

Legislative Assistant to Rep. Pat Williams in the areas of health, social services, women's issues, and the elderly: developed and evaluated legislation; wrote speeches and position papers; and represented Rep. Williams at meetings with Congress, Congressional staff, advocates, and policy-related experts.

Academic Experience

2006-2012

University of Pennsylvania Center for Bioethics
Fellow

2005-present

Johns Hopkins, University of California, University of Maryland, American University, George Washington University, University of Illinois
Guest Lecturer in several graduate and undergraduate courses

1980-83

Harvard University, Director, Seven College Study

Developed, analyzed, and published results of a longitudinal study of the life goals and well-being of 9,000 undergraduates from Barnard, Bryn Mawr, Mount Holyoke, Radcliffe and Harvard, Smith, Vassar, and Wellesley. Hired and managed staff; supervised data collection on seven campuses; developed the budget; designed surveys; wrote articles; gave speeches; and coordinated and chaired planning meetings of faculty and administrators representing the seven colleges.

- 1979-80 Yale Medical School, Departments of Psychiatry and Epidemiology**
 Post-doctoral Fellow in epidemiology. Designed research, analyzed data, and wrote articles on the results of three research projects: social factors influencing the mortality of the elderly poor, treatment for depression, and medical care for battered women. **1978-79 Yale University, Psychology Department, Research Faculty**
 Director of a nationally recognized research project that evaluated and modified the impact of television on children's health habits and behaviors. Designed research, trained teachers, supervised staff, analyzed data, developed lesson plans, and co-authored two books and several articles for professional journals.
- 1977-78 Vassar College, Psychology Department, Assistant Professor**
 Taught Abnormal Psychology, Current Psychotherapies, Personality, and Psychopathology Seminar, and supervised field work and research projects.
- 1974-76 Ohio State University, Psychology Department, Teaching Associate**

Clinical Experience

- 1979 Yale University, Depression Research Unit and Connecticut Mental Health Center.** Therapist for depressed outpatients.
- 1976-77 Worcester State Hospital, Worcester, MA.** Pre-doctoral intern. Inpatient case management and psychological assessment; outpatient individual, couples, family, and group therapy; and training of professionals and paraprofessionals at mental health clinics.
- 1974-76 Ohio State University Counseling Center and Community Mental Health Centers, Columbus, Ohio.** Individual therapy with adults and children, couples therapy, group therapy, psychological assessment, intake interviews, and consultation with schools and day care centers.

Selected Testimony and Invited Presentations 1997-present

Health and Public Policy

Research on Women's Health for the 21st Century. Presented testimony at conference sponsored by the National Institute of Health's Office of Research on Women, Sante Fe, 1997.

Drug Safety and Pregnancy. Invited speaker at workshop co-sponsored by the National Institute of Child Health and Human Development and the FDA, Bethesda, 2000.

The Need for Research: The Benefits of H.R. 1961. Testimony before the Subcommittee on Health of the Committee on Energy and Commerce, U.S. House of Representatives, Washington, D.C., 2001.

We Need to Know More: The importance of studying medical products that are already approved. Invited speaker at FDA's Public Meeting on the Prescription Drug User Fee Act (PDUFA), Washington, D.C., 2001.

Methylmercury in Fish: Risks for Pregnant Women and Children. Invited speaker at FDA's Advisory Panel meeting on a Public Advisory on Methylmercury in Fish, 2002.

Cancer, Prevention, and Federal Policies. Speaker at Congressional briefing in the U.S. Senate, 2003.

When Little Girls Become Women: Early Puberty and Risk Behaviors in Girls. Invited keynote speaker at annual spring training meeting of State of Pennsylvania's teen pregnancy program staff, Harrisburg, 2004.

The Need for Diversity in Clinical Trials of New Medical Products. Invited speaker for the annual conference of the American Medical Women's Association, Washington, DC, 2004.

Conflicts of Interest and the Integrity of NIH Research. Meeting of the NIH Advisory Committee on Conflicts of Interest, Bethesda, 2004.

Scientific Integrity and Women's Health. Panel presentation at the annual meeting on scientific integrity of the Center for Science in the Public Interest, Washington, D.C., 2004

Politics, Science, and Health. Invited speaker at Princeton University roundtable on science and politics, 2004.

Politics and Health. Invited speaker at George Washington University roundtable, 2004.

Working on and off Capitol Hill. Invited speaker for the Women's Research and Education Institute Congressional Fellowship Program, U.S. House of Representatives, Washington, DC, 2005.

Children and Obesity. Keynote speaker at the Delta Kappa Gamma biennial conference for women educators, March 19, 2006.

Everything you Need to know about Women's Health. Keynote speaker at Temple Sinai Sisterhood dinner, Washington, DC, May 18, 2006.

Life after a Congressional Fellowship. Invited speaker for the Women's Research and Education Institute Congressional Fellowship Program, U.S. House of Representatives, Washington, DC, 2006.

Improving the Safety of Medical Products. Invited speaker at Capitol Hill Briefing of the Patient, Consumer, and Public Health Coalition, 2007.

Health Policy Issues and the National Research Center for Women & Families. Invited speaker for the Women's Research and Education Institute Congressional Fellowship Program, U.S. House of Representatives, Washington, DC, 2007.

Political Science: How Federal Priorities Affect Health Research and Policy. Invited speaker for Health Policy Fellowship Program, Philadelphia College of Osteopathic Medicine, 2007.

Politics v. Science v. Anecdote on Capitol Hill, presentation to faculty and students at the University of Pennsylvania Center for Bioethics, Philadelphia, 2007.

The FDA and Women's Health, presentation at the annual meeting of the American Public Health Association, Washington, D.C., 2007.

Medical Devices and User Fees, Testimony before the Health Subcommittee of the Energy and Commerce Committee, U.S. House of Representatives, 2007.

Are Medical Devices Safe? Shortcomings of the Approval Process, Testimony before the Health Subcommittee of the Energy and Commerce Committee, U.S. House of Representatives, 2007.

Clinical Trials to Ensure Public Health, Invited speaker at the Food and Drug Law Institute, 2009.

Improving Cancer Treatment and Prevention, keynote speaker for the Cancer Awareness Program of the Blacks in Government and The Wellness Program, Department of Energy, 2009.

Improving Safety for Cardiac Patients, invited speaker, Transcatheter Cardiovascular Treatment (TCT) annual conference, 2010.

Public Health Implications of the Device Approval Process, Invited speaker at FDA Forum on the 510(k) Approval Process, 2010.

Surgical Mesh and The Need for Patient-Centered Outcome Data, Invited speaker at Congressional briefing, U.S. House of Representatives, 2011.

Medical Devices and Public Health, Testimony before the Aging Committee of the U.S. Senate, 2011.

The Sentinel Initiative: Consumer Perspective, invited panel speaker at Brookings Institution conference, 2012.

Changes you can make to Prevent Cancer, Department of Energy Blacks in Government annual meeting, 2012

Consumer Perspective on Medical Device Approval Criteria, invited speaker on panel with FDA officials at Food Drug Law Institute conference, 2012

Safety, Effectiveness, and Public Health, invited speaker at annual meeting of Consumers United for Evidence-based Healthcare/Cochrane Collaborative, 2012.

What Seniors Need to Know about Medications, invited speaker at meeting of IBM's Rusty Blues (retirees), 2012.

Compounding Pharmacies and Public Health, invited speaker at Congressional press conference hosted by Rep. Ed Markey, 2012.

FDA Regulatory Standards for Medical Devices, speaker at Briefing in U.S. House of Representative and U.S. Senate, 2012.

Medical Device Recalls, speaker at Congressional Briefing hosted by George Mason University Law School, 2013.

Standards for FDA Approval: Drugs v. Devices, speaker at Georgetown Medical School conference on Medical Behavior in a Commercial World, 2013.

The FDA Approval Process: Implications for Public Health, speaker at Congressional Briefings, U.S. House of Representative and U.S. Senate, 2013

FDA Approval Process: What Physicians Need to Know, speaker at the annual meeting of the National Physicians Alliance, 2013

Medical Device Approval Criteria, speaker at Leadership Conference for the American Medical Students Association, 2013.

The Impact of FDA Approval Standards on Patient Health, speaker at briefing at the U.S. Senate, 2014

Safety and Effectiveness of Drugs and Devices, speaker at Conference sponsored by Harvard Medical School, American Association for the Advancement of Science, and National Center for Health Research, 2014.

Expedited Reviews of Drugs and Devices, speaker at annual meeting of Consumers United for Evidence-Based Medicine (CUE), 2014.

Is a Medical Device Safe if it Isn't Proven Safe?, speaker at the annual meeting of the National Physicians Alliance, 2014.

The Impact of FDASIA on Medical Devices, invited speaker at Senate HELP Committee briefing, U.S. Senate, 2014

How FDA Approval Policies Affect Medicaid, meeting of the Drug Effectiveness Review Project, Oregon Health and Science University, 2014.

The Impact of Changing FDA Approval Standards, invited speaker at Senate HELP Committee briefing, U.S. Senate, 2015

The Challenge of Well-Funded Medical Lobbying, speaker at the annual meeting of the National Physicians Alliance, 2015.

FDA and Your Patients' Health: What Does Safe and Effective Actually Mean?, Grand Rounds, University of Maryland Medical School, 2014.

Shortcuts for Getting Medical Products to Market, invited speaker at annual meeting of Consumers United for Evidence-based Healthcare/Cochrane Collaborative, 2014

Standards for Safe and Effective Medical Treatments, invited speaker at Conference of Consumer Reports Safe Patient Project, 2015.

The Role of Patients and the Public in FDA Approval Decisions, Invited speaker at Harvard Medical School Bioethics Seminar Series, 2016

Public Health Considerations, FDA, and Opioids, invited speaker at meeting regarding Opioid Addiction of the National Academies of Sciences, Engineering, and Medicine, 2016.

How Changes to the Affordable Care Act Would Affect the Health of Women with Disabilities, presentation at Cerebral Palsy Foundation Workshop supported by CPF PCORI Engagement Award, 2016.

What Patients Need to Know About the FDA, presentations at 4 Patient Training Workshops supported through NCHR's PCORI Engagement Award, 2015-2017

The Importance of Patient-Centered Research, invited speaker at PCORI annual conference, 2017.

Legislation Affecting the Health of Women and Children, invited speaker at annual meeting of Delta Kappa Gamma International (women educators), 2018.

What the FDA Can Do to Reduce the Opioid Epidemic, invited speaker at FDA public forum on opioids, 2018.

Priorities for the Consumer Product Safety Commission in 2018-2019. Speaker at annual public meeting of the Consumer Product Safety Commission, 2018.

Science, Regulations, and Human Health invited speaker at the ABA Administrative Law and Regulatory Practice Institute, 2018.

Copycat Gun Violence, Testimony before the Virginia Crime Commission, Richmond, 2019.

Lead and Toxic Chemicals on Children's Playgrounds, Key speaker at CDC Childhood Lead Poisoning Prevention Program Annual Meeting, Atlanta, 2023

The Risks of PFAS and Other Chemicals in Artificial Turf and Children's Rubber Playground Surfaces, invited speaker at more than a dozen State and local government hearings in Arizona, California, Connecticut, Maryland, Massachusetts, New Jersey New York, 2017-present

Recommendations to Improve FDA Over-The-Counter User Fees, speaker at FDA OMFUFA Stakeholders Meeting, 2024.

Lead, Heavy Metals, and Chemical Exposures on Artificial Turf, Playgrounds, Rubber Mulch, and Rubber Tiles, Invited speaker at Idaho Environmental Health Association annual education conference, Boise, 2024.

The Impact of Artificial Turf and Playground Surfaces on Children's Health, speaker at the Consumer Products Safety Commission annual meeting on CPSC priorities, 2024.

FDA Regulations, Small Businesses, Innovation, and Patient Safety, Testimony at House of Representatives Small Business Committee hearing on "Stifling Innovation: Examining the Impacts of Regulatory Burdens on Small Businesses in Healthcare," 2024

Over-the-Counter User Fee Improvements for OMFUFA II, Invited presentation at the FDA meeting on OMFUFA, 2024.

Medical Device User Fee Improvements for MDMUFA VI, Invited presentation at the FDA meeting on MDMUFA VI improvements, 2025

Congressional Policy Reports:

The Department of Education's Limits on Publications: Saving Money or Censorship? House Report 99-978, 1986.

Occupational Health Hazard Surveillance: 72 Years Behind and Counting. House Report 99-979, 1986.

Mismanagement of the Office of Human Development Services: Undermining Programs for Children, the Disabled, and the Elderly. House Report 100-57, 1987.

From Back Wards to Back Streets: The Failure of the Federal Government in Providing Services for the Mentally Ill. House Report 100-541, 1988.

Barriers to Prenatal Care: Can the U.S. Do More With Less? House Report 100-574, 1988.

Infertility in America. House Report 101-389, 1989.

The Federal Role in Determining the Medical and Psychological Impact of Abortion on Women. House Report 101-392, 1989.

<u>Are Scientific Misconduct and Conflicts of Interest Hazardous to Our Health?</u>	House Report 101-688, 1990.
<u>Mismanagement in Programs for the Homeless: Washington, D.C. as a Case Study.</u>	House Report 102-366, 1991.
<u>Is Science for Sale?: Transferring Technology from Universities to Foreign Corporations.</u>	House Report 102-1052, 1992.
<u>Is the FDA Protecting Consumers from Dangerous Off Label Uses of Medical Drugs and Devices?</u>	House Report 102-1064, 1992.
<u>The FDA's Regulation of Silicone Breast Implants.</u>	Congressional Staff Report, 1993.
<u>Is Military Research Hazardous to Veterans' Health?: Lessons Spanning Half a Century.</u>	Congressional Staff Report, 1994.

Opinion Articles in National Publications

Dr. Zuckerman's op-eds have been published in *Washington Post*, *Los Angeles Times*, *Detroit Free Press*, *San Jose Mercury News*, *Charlotte Observer*, *St. Paul Pioneer Press*, *Courier News* (NJ), *Washington Times*, and numerous other newspapers, and been distributed on the LA Times-Washington Post news wire, the Knight-Ridder news wire, and syndicated through other media outlets.

A sample of op-ed publications include:

"What the FDA Should Learn From the RU-486 Marathon" published in October 2000 by *The Washington Post*

"Claims of 'safer' cigarettes must be subjected to FDA scrutiny" published in December 2001 in the *Charlotte Observer* and the *Lexington Herald Leader*

"Do Breast Implants Increase Health Risks?" published in April 2002 in *Physician's Weekly*

"Is Drug Safety Being Enron'd?" published in May 2002 in the *Detroit Free Press*, *Saint Paul Pioneer Press*, the (Charleston, WV) *Gazette-Mail*, and other Knight Ridder newspapers

"The Bad News About New Drugs Comes Very Late" published in July 2002 in *The Sacramento Bee* and other Knight Ridder newspapers

"Public Needs FDA to Improve Watchdog Policies on Drugs" published in July 2002 in the *Detroit Free Press* and other Knight Ridder newspapers

"Finding Relief for Working Moms" published in September 2002 by the New York Times syndicate

"Hype in Health Reporting" published in September/October issue of *Extra!* Magazine.

"Dangerous Laxity on Medical Implant Safety" published in October 2002 in the *Los Angeles Times*

"Taking Beauty Standards to Extremes" published in January 2003 in the *Tallahassee Democrat* and other Knight Ridder newspapers

“A Split Decision on Breast Implants” published in October 2003 in *The Washington Times*

“Do We Need to Give Up Tuna?” published in December 2003 by Knight-Ridder newswire.

“[The Movies, Cigarettes, and our Children](#),” published in July 2004 in the Biloxi (MS) *Sun Herald*, *The Record* (Hackensack, NJ), *Lexington Herald Leader*, and other Knight Ridder newspapers

“Be all you can be—in a C-Cup?” published in August 2004 in the *Houston Chronicle*, *Tulsa World* and other Knight Ridder newspapers

“No Supersizing This Year!” published in September 2004 in the *Milwaukee Journal Sentinel*, *Los Angeles Daily News*, *The (Fredericksburg, VA) Free Lance Star*, the *Peoria (IL) Journal Star*, and other Knight Ridder newspapers

“FDA Needs to Think Long-Term” published in December 2004 in the *Albany Times-Union*, *Lexington Herald-Leader*, *The Miami Herald*, *el Nuevo (Miami) Herald* and other Knight Ridder newspapers

“New Year’s Resolutions for the U.S.” published in January 2005 in *The Sacramento Bee*, *Duluth News-Tribune*, *Augusta (GA) Chronicle*, *Watertown (NY) Daily Times* and other Knight Ridder newspapers

“Bad Year for the FDA” published in May 2005 in the *Duluth News Tribune*, *Tulsa World*, and other Knight Ridder newspapers

“[Safe Enough?](#)” published in August 2005 in *The Washington Times*

“[Safe Enough for Political Use?](#)” published in September 2005 in *Houston Chronicle*, *Miami Herald*, and other Knight Ridder newspapers

“Shopping for Children has Become a Risky Proposition” published in November and December 2005 in the *San Jose Mercury News*, *Austin American-Statesman*, *Duluth News Tribune*, *Whittier (CA) Daily News* and other Knight Ridder newspapers

“FDA needs help to heal itself as it turns 100” published in July 2006 in the *Augusta Chronicle*, *Billings Gazette*, and other Knight Ridder/McClatchy newspapers

“Take your mom, sister, wife, or friend for a mammogram” published in October 2006 in *The Saint Augustine Record*, *Lexington Herald-Ledger*, and other Knight Ridder/McClatchy newspapers

“Apples and Oranges and Safe Medications,” published in June 2007 in the *Anchorage Daily News*, *The Bellingham Herald*, *Beaufort Gazette*, *Billings Gazette*, *Sacramento Bee*, *South Carolina Herald*, *The News & Observer*, *The New York Sun*, *Press of Atlantic City*, *The Southern Illinoisan*, *Times Herald-Record*, *Tri-City Herald*, and *Winona Daily News*, and other McClatchy newspapers

“Adding Bite to FDA Screening,” published in *The Boston Globe*, April 17, 2007.

“Playing With the Band,” published in *New York Times*, January 12, 2011

“Can the War on Cancer be Won?: A Surprising Answer, *Huffington Post*, https://www.huffpost.com/entry/can-the-war-on-cancer-be_n_5765676

“Which Cancer Drugs Actually Work? Many Unanswered Questions Threaten Patients and Families,” *Rodale.com*, November 13, 2014 <http://www.mariasfarmcountrykitchen.com/cancer-drugs/comment-page-1/>

“21st Century Cures Act: Yes or No? No: Act’s Promise of Quick Cures Is a Brew of Ultra-Hype Mixed With Snake Oil,” syndicated publication in *Chicago Tribune*, *Baltimore Sun*, *Orlando Sentinel*, *Sacramento Bee*, and others, July 21, 2016

“Congress Shouldn’t Pass FDA Reform Bills Without Addressing Patient Safety and Drug Prices,” *The Health Care Blog*, November 23, 2016, <https://thehealthcareblog.com/blog/2016/11/23/congress-shouldnt-pass-fda-reform-bills-without-addressing-patient-safety-and-drug-prices/>

“Right to Try National Law Would Exploit False Hope” published in 21 newspapers including, *Chicago Tribune*, *Sacramento Bee*, *McAllen (TX) Valley Voice*, *Bellingham (WA) Herald*, and others: March 16-20, 2017.

“Breast Implants Linked to Rare Cancer” *Our Bodies Ourselves*, March 28, 2017, <https://www.ourbodiesourselves.org/2017/03/news-breast-implants-linked-rare-cancer/>

“Tests for Covid-19: Has the FDA said yes too many times?” By Robert Kaplan and Diana Zuckerman, *The Hill*, May 6, 2020. <https://thehill.com/opinion/healthcare/496403-tests-for-covid-19-has-the-fda-said-yes-too-many-times/>

“Medicare has different standards than the FDA. That’s how it should be.” *STAT News*, February 2, 2024. <https://www.statnews.com/2024/02/02/medicare-cms-fda-approval-drugs-safety-older-americans/>

The FDA’s misguided thinking on antibiotics, By Diana Zuckerman and John H. Powers III, *STAT News*, February 10, 2025. <https://www.statnews.com/2025/02/10/antibiotic-resistant-infections-treatments-research-fda/>

Media Interviews and Workshops to Train Journalists:

Dr. Zuckerman has been interviewed for dozens of news programs and talk shows on public television, ABC, CBS, NBC, CNN, Fox, Fox News, Canadian and European television programs, and National Public Radio *All Things Considered* and *Marketplace*, Canadian Public Broadcasting, and other radio programs across North America and the United Kingdom. She has been quoted in *New York Times*, *Washington Post*, *Wall Street Journal*, *USA Today*, *Boston Globe*, *Los Angeles Times*, *Detroit Free Press*, and dozens of other newspapers, 1982-present. In addition, her work has been reported on *60 Minutes*, *Nightline*, *20/20*, *New York Times*, *Washington Post*, *USA Today*, *Life*, *US News and World Report*, *Time*, *Newsweek*, *McCalls*, *Glamour*, *Self*, *Seventeen Magazine*, and numerous other newspapers and magazines, as well as *ABC News*, *NBC News*, *CBS News*, *Fox News*, *CNN*, *Public Television*, *CNBC*, and *MSNBC*.

In March 2019, Dr. Zuckerman initiated and hosted the first of two training workshop on how to understand and explain health research results, with the support of the federally funded Patient Centered Outcome Research Institute (PCORI). She recruited and selected 30 journalists from across the country as faculty and participants, including major media such as *NPR*, *New York Times*, *Bloomberg*, and *AP*; trade press such as *MedPageToday* and *DrugWatch*, and freelance writers for large and small media outlets. Other faculty were from National Cancer Institute, *JAMA*, Georgetown Medical Center, and George Washington University.

Testimony before Congress, Parliament, and Federal Agencies:

Dr. Zuckerman has testified dozens of times on health policy issues. In addition to the Congressional testimony and selected presentations at Congressional briefings, she has testified before the Canadian Parliament Committee

on Health, FDA Advisory Committees and Policy Forums, EPA Advisory Committees, Department of Agriculture Advisory Committees, and Committees of the Institute of Medicine, 1999-present. Topics include safety of medical products, risks and benefits of cancer screening, the importance of comparative effectiveness research, and the impact of environmental exposures on human health.

Selected Recent Articles, Monographs, and Book Chapters (2006-present)

Zuckerman, D.M. (2006) Breast Implants: Making an Informed Decision, Johns Hopkins Advanced Studies in Medicine.

Zuckerman, D.M. (2006) FDA Advisory Committees: Does Approval Mean Safety? National Research Center for Women & Families.

Zuckerman, D.M. (2007). A Consumer Advocate's Perspective on Medical Device Safety. In Medical Device Epidemiology and Surveillance, S. L. Brown, R.A. Bright, and D. Tavis (ed.). John Wiley & Sons.

Zuckerman, D. and Abraham, A. (2008). Teenagers and Cosmetic Surgery, Journal of Adolescent Health, **43**, 318-324.

Zuckerman, D. (2008) Do Conflicts of Interest Undermine FDA Approval Decisions? Regulatory Affairs Journal, **16**, 309-310.

Zuckerman, D. (2009) The Ethics of Inclusion and Exclusion in Clinical Trials: Race, Sex, and Age, In The Penn Center Guide to Bioethics, Vardit Ravitsky, Autumn Fiester, and Art Caplan (eds.), Springer.

Zuckerman, D.M. (2010) Reasonably safe? Breast Implants and Informed Consent, Reproductive Health Matters, **18**, 94-1-2.

Zuckerman D.M., Brown P., Nissen S.E. (2011). In Reply, Archives of Internal Medicine, **171**(11), 1045

Zuckerman D.M., Brown P., Nissen S.E. (2011). In Reply, Archives of Internal Medicine, **171**(21), 1963.

Abraham, A. and Zuckerman, D. (2011) Adolescents, Celebrity Worship, and Cosmetic Surgery, Journal of Adolescent Health, **49**, 453-4.

Zuckerman, D., Booker, N, and Nagda, S. (2012) Public Health Implications of Difference in US and European Union Regulatory Policies for Breast Implants, Reproductive Health Matters, **20** (40),102-111.

Terplan M. and Zuckerman D. (2013) Comment on 'Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism'. Journal of Family Planning and Reproductive Health Care, **39**(4):304.

Zuckerman, D. (2013) Hip Implant Failure for Men and Women: What and When We Need to Know
Comment on "Sex and Risk of Hip Implant Failure" JAMA Internal Medicine, **173**(6): 442-443.

Yttri J. and Zuckerman D. (2013) Addressing the need for new antibacterials". The Lancet Infectious Diseases, **13**(10):834.

- Fox, D.M. & Zuckerman, D.M. (2014) Regulatory Reticence and Medical Devices, Milbank Quarterly, 92(1): 151-159.
- Zuckerman D.M., Brown P. & Das A. (2014) Lack of Publicly Available Scientific Evidence on the Safety and Effectiveness of Implanted Medical Devices, JAMA Internal Medicine, 174(11): 1781-1787.
- Doamekpor L.A. and Zuckerman D.M. (2014) Lack of diversity in cancer drug clinical trials may exacerbate racial disparities in mortality rates. Cancer Epidemiology, 38(5):645-46.
- Zuckerman D.M. and Brown P. (2015) Sufficiency of Information in 510(k) Summaries-Reply. JAMA Internal Medicine, 175(5):864.
- Zuckerman, D.M.. (2015) Screening for Lung Cancer, To Be or Not To Be Covered by Medicare? Journal of Thoracic Imaging, 30(1): 24-28.
- Gonsalves, G. & Zuckerman, D.M. (2015) Will 20th Century Patient Safeguards Be Reversed in the 21st Century? BMJ, 350 h1500.
- Zuckerman, D.M. & Doamekpor L.A. (2015) More Data Are Needed for Essure Hysteroscopic Sterilization Device. Contraception 91 (6): 520
- Zuckerman, D.M. (2015) Understanding the Controversies Over a Groundbreaking New Health Care Law. <http://www.milbank.org/the-milbank-quarterly/the-op-eds/understanding-the-controversies-over-a-groundbreaking-new-health-care-law>
- Zuckerman, D.M., Jury, N.J. & Silcox, C.E. (2015) 21st Century Cures Act and similar policy efforts: at what cost? BMJ, 351:h6122.
- Zuckerman, D.M. & Silcox, C.E. (2016) The Challenges of Informed Consent When Information and Time are Limited. In Informed Consent: Procedures, Ethics and Best Practices, Winston Hammond (ed.), Nova Science.
- Zuckerman D. (2016). When Will Presidential Candidates Ask, "What Do Women Want in Health Care?" American Journal of Public Health, 106(5):790-1.
- Zuckerman D.M., Kennedy C.E., Terplan M. (2016) Breast Implants, Self-Esteem, Quality of Life, and the Risk of Suicide. Women's Health Issues, 26(4):361-65.
- Zuckerman D.M. (2017) A Major Shortcoming in the Public Health Legacy of the Obama Administration. Am Journal of Public Health 2017;107(1):29-30.
- Zuckerman, D. (2017). How to Kill Obamacare: Death by 1,000 Cuts? The BMJ Opinion, BMJ.
- Zuckerman, D. (2017). What Does It Mean to March for Women in 2017? The BMJ Opinion, BMJ.
- Rupp, T. & Zuckerman, D.M. (2017) Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints. JAMA Internal Medicine, 177(2): 276-277.
- Zuckerman D.M. (2017) Setting the Record Straight on FDA Approvals in Oncology-Reply. JAMA Internal Medicine 177(8):1222-23.

- Ronquillo, J.G. & Zuckerman, D. M. (2017) Software-Related Recalls of Health Information Technology and Other Medical Devices: Implications for FDA Regulation of Digital Health. Milbank Quarterly. 95(3): 535-553.
- Ronquillo J.G., Zuckerman D.M. (2017) Electronic Health Records. Annals of Internal Medicine, 166(7):536-36.
- Zuckerman, D., Tomes, M & Murphy, A. (2017) Are Gummy Bear Breast Implants the Safer Implants? In Breast Implants, Rene Simon (ed), Nova Science.
- Zuckerman, D.M. (2017) Can the FDA Help Reduce Drug Prices or the Cost of Medical Care? American Journal of Public Health, 107(11): 1752-1754.
- Fox-Rawlings S., Gottschalk L.B., Doamekpor L., Zuckerman D.M. (2018) Diversity in Medical Device Clinical Trials: Do We Know What Works for Which Patients? Milbank Quarterly, 96 (3); 499-529.
- Zuckerman, D.M. (2021). Emergency Use Authorizations (EUAs) Versus FDA Approval: Implications for COVID-19 and Public Health. American Journal of Public Health. 111(6): 1065-1069.
- Garipey AM, Lewis C., Zuckerman D., Tancredi D., Murphy E., McDonald-Mosley R. et al. (2022) Comparative effectiveness of hysteroscopic and laparoscopic sterilization for women: a retrospective cohort study. Fertility and Sterility. 117(6):1322-1331.
- Schwarz EB, Lewis C.A., Dove M.S., Murphy E., Zuckerman D, Nunez-Eddy C. et al. (2022) Comparative Effectiveness and Safety of Intrauterine Contraception and Tubal Ligation. Journal of General Internal Medicine. 37(16):4168-4175.
- Bendicksen L., Zuckerman D.M., Avorn J., Phillips S., Kesselheim A.S. (2023) The Regulatory Repercussions of Approving Muscular Dystrophy Medications on the Basis of Limited Evidence. Annals of Internal Medicine, 176(9): 1251-1256.
- Powers J.H, Zuckerman, D.M. (2025) Rethinking Antimicrobial Resistance: Focusing on Patients Instead of Pathogens. Medical Research Archives, 13(3):doi.org/10.18103/mra.v13i3.6291